Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm. | Sanofi has backed the $75 million series B of a rhinovirus-focused ...

Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, today announced a $75 million ...

Please provide your email address to receive an email when new articles are posted on . More than a quarter of children with refractory wheeze were positive for rhinovirus despite a lack of symptoms.

Rhinovirus infections may ramp up genes that help the lung airway defend itself against SARS-CoV-2. In this study, participants with a rhinovirus infection in the previous 30 days had a 48% lower risk ...

During the height of the pandemic, COVID-19 restrictions caused a drop in cases of other respiratory viruses, like rhinovirus. But now, it seems, rhinovirus is back in a big way. The virus, which ...

Using a laboratory model of the human nose, scientists have investigated why the severity of common-cold infections varies so widely between individuals.

September 16, 2010 (Boston, Massachusetts) — Despite expectations to the contrary, the use of a hand disinfectant did not achieve significant protection against transmission of rhinovirus-associated ...

Rhinoviruses cause serious morbidity and mortality as the major etiological agents of asthma exacerbations and the common cold. A major obstacle to understanding disease pathogenesis and to the ...

Both RSV and rhinovirus are viruses that typically lead to common and mild infections. The majority of the time, symptoms of both resolve on their own in about a week. However, either can lead to ...